key: cord-0689348-8iyo72do authors: Perkins, Gavin D.; Couper, Keith; Connolly, Bronwen; Baillie, J. Kenneth; Bradley, Judy M.; Dark, Paul; De Soyza, Anthony; Gorman, Ellen; Gray, Alasdair; Hamilton, Louisa; Hart, Nicholas; Ji, Chen; Lall, Ranjit; McGowan, Nicola; Regan, Scott; Simonds, Anita K.; Skilton, Emma; Stallard, Nigel; Stimpson, Emily; Yeung, Joyce; McAuley, Daniel F. title: RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial date: 2020-07-29 journal: Trials DOI: 10.1186/s13063-020-04617-3 sha: 02cb026811c8c428d8f094ec5a5bb233ba784f51 doc_id: 689348 cord_uid: 8iyo72do OBJECTIVE: The trial objective is to determine if Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) is clinically effective compared to standard oxygen therapy in patients with confirmed or suspected COVID-19. TRIAL DESIGN: Adaptive (group-sequential), parallel group, pragmatic, superiority randomised controlled, open-label, multi-centre, effectiveness trial. PARTICIPANTS: The trial is being conducted across approximately 60 hospitals across England, Wales, Scotland, and Northern Ireland. Inpatients at participating hospitals are eligible to participate if they have respiratory failure with suspected or proven COVID-19, and meet all of the inclusion criteria and none of the exclusion criteria. Inclusion criteria: 1) Adults ≥ 18 years; 2) Admitted to hospital with suspected or proven COVID-19; 3) Receiving oxygen with fraction of inspired oxygen (FiO(2)) ≥0.4 and peripheral oxygen saturation (SpO(2)) ≤94%; and 4) Plan for escalation to tracheal intubation if needed. Exclusion criteria: 1) Planned tracheal intubation and mechanical ventilation imminent within 1 hour; 2) Known or clinically apparent pregnancy; 3) Any absolute contraindication to CPAP or HFNO; 4) Decision not to intubate due to ceiling of treatment or withdrawal of treatment anticipated; and 5) Equipment for both CPAP and HFNO not available. INTERVENTION AND COMPARATOR: Intervention one: Continuous positive airway pressure delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion. Intervention two: High-flow nasal oxygen delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion. Comparator group: Standard care- oxygen delivered by face mask or nasal cannula (excluding the use of continuous positive airway pressure or high-flow nasal oxygen). Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion. Intervention delivery continues up to the point of death, tracheal intubation, or clinical determination that there is no ongoing need (palliation or improvement). MAIN OUTCOMES: The primary outcome is a composite outcome comprising tracheal intubation or mortality within 30 days following randomisation. Secondary outcomes include tracheal intubation rate, time to tracheal intubation, duration of invasive ventilation, mortality rate, time to mortality, length of hospital stay, and length of critical care stay. RANDOMISATION: Participants are randomised in a 1:1:1 ratio to receive either continuous positive airway pressure, high-flow nasal oxygen or standard care. Due to the challenging environment of study delivery, a specific intervention may not always be available at the hospital site. The study uses two integrated randomisation systems to allow, where required, the site to randomise between all three interventions, between CPAP and standard care, and between HFNO and standard care. System integration ensures maintenance of balance between interventions. Randomisation is performed using a telephone-based interactive voice response system to maintain allocation concealment. The randomisation sequence was computer-generated using the minimisation method. Participant randomisation is stratified by site, gender (M/F), and age (<50, >=50 years). BLINDING (MASKING): The nature of the trial interventions precludes blinding of the researcher, patient and clinical team. Primary and secondary outcomes are all objective outcomes, thereby minimising the risk of detection bias. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 4002 participants (1334 to be randomized to each of the three study arms) TRIAL STATUS: Current protocol: Version 4.0, 29(th) May 2020. Recruitment began on April 6, 2020 and is anticipated to be complete by April 5, 2021. The trial has been awarded Urgent Public Health status by the National Institute of Health Research on 13(th) April 2020. TRIAL REGISTRATION: ISRCTN, ISRCTN16912075. Registered 6(th) April 2020, http://www.isrctn.com/ISRCTN16912075 FULL PROTOCOL: The full protocol (version 4.0, 29(th) May 2020) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). . Mental Capacity Act Emergency Consent framework 22-23 Table 2 . Trial assessments 27 Table 3 . Relationship of SAEs to trial intervention 29 Table 4 . Critical values expressed as one-sided p-values for a test 34 with four equally spaced looks Determining the most effective form of ventilatory support for patients with COVID-19 is therefore paramount to ensure optimum therapy is delivered to patients, and to protect UK vital critical care resources and infrastructure. Findings from this trial will also have the potential to inform global ventilation practice for patients with COVID-19. There is currently no direct evidence to support the use of HFNO in patients with COVD-19 6 8 . A qualitative analysis of 13 studies on tolerability and comfort suggested that HFNO was associated with improved patient comfort and dyspnea scores 8 . In contrast, other recent systematic reviews and meta-analyses have demonstrated a benefit of HFNO in reducing intubation compared with conventional oxygen (RR 0.85, 95% CI 0.74 to 0.99), but similarly no effect on risk of death or ICU length of stay [9] [10] [11] . Reducing the need for intubation is a clinically meaningful outcome, with additional important benefits for healthcare resource utilisation. Current Surviving Sepsis Campaign (SSC) COVID-19 guidelines make a weak recommendation, based on low quality evidence, for using HFNO over conventional oxygen therapy 6 . A similar strength of recommendation is made for using HFNO over NIV 6 , based on contrasting evidence around the effectiveness for HFNO to reduce mortality, need for intubation, and ICU length of stay 9 12 and potential for greater patient tolerability for HFNO 12 . Guidelines from the Australia and New Zealand Intensive Care Society (ANZICS) similarly recommend HFNO for patients presenting with hypoxia 13 . Both sets of guidelines do however, advise close monitoring of patients receiving either HFNO in a setting of sufficient acuity to enable controlled intubation in the event of deterioration given the high risk of failure 6 13 . There are currently no data available on the use of CPAP directly in patients with COVID-19. A number of trials have explored the effectiveness of CPAP in ARF. These trials provide some evidence that CPAP has a role in improving important outcomes such as progression to intubation, length of stay in ICU and/or hospital. In a 2015 Cochrane systematic review and meta-analysis, Faria et al 14 There is no direct evidence to support the use of NIV in patients with hypoxic respiratory failure, with some reports of increased risk to healthcare workers of exposure to infection 6 . Previous metaanalyses where reductions in intubation and mortality have been demonstrated with NIV have been in patient populations less relevant to COVID-19 6 . Failure rates are generally high with use of NIV outside of cardiogenic pulmonary oedema. Should other pathophysiology be present e.g. acute hypercapnic respiratory failure, NIV may be considered 13 17-19 . Surviving Sepsis Campaign guidelines recommend HFNO over NIV 6 , based on contrasting evidence around the effectiveness for HFNO to reduce mortality, need for intubation, and ICU length of stay 9 12 and potential for greater patient tolerability for HFNO 12 . In patients with COVID-19, where HFNO is not available and there is no urgent need for intubation, a trial of NIV with close monitoring and short-interval assessment for deterioration may be considered (weak recommendation, very low quality evidence) 6 . In adult patients, with suspected or confirmed COVID-19, CPAP or HFNO are more effective than standard care for reducing the rate of intubation and / or mortality. We will aim to recruit a maximum of 4002 patients to explore this hypothesis. However, as this is an adaptive trial (group-sequential) in design, we will review the data at each stage using formal Version 4.0 29-May-2020 16(47) interim analyses and continue with all arms or drop an intervention arm if required. The trial will therefore stop early and not require this total sample size if an intervention appears to be effective at an interim analysis. This review of the literature highlights that whilst there is some evidence to support current ventilation options for patients with COVID-19, there is little evidence to guide the relative efficacy of these interventions especially HFNO versus CPAP versus standard care oxygen therapy prior to intubation. Importantly, evidence is derived from the general ARF population; there are no COVID-19-specific data. Evidence on the relative effectiveness of these interventions is paramount to ensuring that critically ill patients with COVID-19 are optimally managed in terms of oxygen requirements and that progression to intubation is minimised. There is clear clinical uncertainty as evidenced in the contrasting recommendations amongst existing sets of recommendations 6 13 17 . In selecting the interventions for investigation in this trial, we have elected to compare the effects of HFNO and CPAP against standard care. We have elected not to examine NIV due to the uncertainty around its applicability to the COVID-19 population and the clinical nature of respiratory impairment in these patients. This trial will provide important data to clarify current national recommendations on the preferred mode of non-invasive respiratory support 17 . We have also reviewed the experiences to date from other countries and relevant literature to support treatment options in patients admitted with suspected or confirmed COVID-19 and developing hypoxia. Yang et al 20 have recently published the first series of 52 patients from the China COVID-19 crisis. They highlight that HFNO and mechanical ventilation (either non-invasive or invasive) was the main supportive treatment for these critically ill patients. Many practical drivers have been highlighted that influence the use of these options. It is a deep concern in some areas that the demand for oxygen therapy will outweigh the ability to provide it to patients. For those interventions that require equipment there is huge dearth of equipment available and for some interventions (such as NIV) there is substantial specialist training required to deliver the intervention optimally. This is balanced against the absolute need to reduce the number of patients requiring intubation given the imbalance between ventilator provision and likely demand. The trial will recruit patients in UK-based hospitals and centres to provide care to COVID-19 patients in England, Wales, Scotland and Northern Ireland, many of whom will lack capacity to consent due to the nature of the underlying disease process. It is likely that patients eligible for the trial will lack capacity, primarily due to acute confusion secondary to hypoxia and infection. Patients will be assessed for capacity in the first instance. Those with capacity will be provided with information about the trial and asked to give verbal consent prior to enrolment. Given the urgent need to initiate treatment and the context in which the trial will operate (e. Operating Procedures (SOPs). Adults without capacity will not be recruited from Scotland. All data will be stored securely and held in accordance with the Data Protection Act 2018. The trial will be reported in line with the CONSORT ( The main trial will take place in NHS hospitals (in England, Wales, Scotland and Northern Ireland) or The trial will be an adaptive (group-sequential), pragmatic, randomised controlled, open-label, multi-centre, effectiveness trial to determine if the use of CPAP or HFNO reduces intubation or death (mortality), within 30 days. We will test each of the intervention against standard care, and if required, drop one of the interventions if there is evidence of harm or ineffectiveness. Patients with suspected or confirmed COVID-19 will be eligible for randomisation when FiO2>0.4 and SpO2<94%, in a 1:1:1 ration to receive either CPAP, HFNO, or standard care (excluding either of the two treatments). Data will be recorded by participating ICUs until hospital discharge, and all surviving patients will be followed up to 30 days. The primary objective of this trial is to determine if CPAP or HFNO is clinically effective compared to standard care in relation to intubation and mortality in patients with confirmed or suspected COVID-19. The secondary objectives for this study are to assess in-hospital patient data in terms of their stay. The primary outcome is a composite outcome comprising intubation or mortality within 30 days. If necessary, patients will be followed up to ascertain all-cause mortality rates at 30 days, using NHS Digital, the Intensive Care National Audit and Research Centre (ICNARC) and equivalent NHS data linkage in the devolved nations. Intubation will be obtained from hospital data. We will collect data on: -Adverse events -Serious adverse events The eligibility criteria are designed to include those who reflect the general population of patients with confirmed or suspected COVID-19 and who may benefit from the therapeutic interventions. Patients are eligible to be included in the trial if they meet the following criteria: We will be using the emergency research consent process. The PI will retain overall responsibility for conduct of the trial at their site. England, Wales and Northern Ireland Patients will be assessed for capacity. Patients with capacity will be provided with verbal information about the trial and given a copy of the written participant information sheet. They will be given adequate time to review the information sheet and ask questions. Due to ongoing concerns regarding risk of infection transmission, verbal consent only will be sought and documented on a study form and in the patient hospital records. Where a patient objects at this point they will not be entered into the study. For patients who lack capacity, it is not practical to consult a personal consultee or independent registered medical practitioner prior to enrolment without placing the potential participant at risk of harm from delaying treatment. These processes will also not be feasible or safe to undertake in order to minimise risk of viral transmission to those involved. Significant limitations have been placed on the visitation of COVID-19 patients and therefore a personal consultee is unlikely to immediately be available, and to attempt contact via telephone will delay treatment. Pressures on clinical services will make it impractical to identify an appropriate independent medical practitioner. In accordance with the legislation in England, Wales and Northern Ireland, as action needs to be taken as a matter of urgency, the Research Ethics Committee has authorised enrolment prior to obtaining informed consent. Once the urgency of the situation has passed, consent to continue will be sought from the patient (if capacity returns) or consultee. This approach is guided by a published Further details of the rationale for our approach are detailed in Table 2 and can be seen in figure 2, and our steps for obtaining consent following initial enrolment are described in Section 2.8.1. There is an urgent need to determine the optimum strategy to manage COVID-19 patients with worsening respiratory failure. This proposal has been commissioned to answer a research question that is considered to be of high priority by the UK clinical community. Is there uncertainty about treatment? There are perceived benefits to each study intervention, and each is in widespread use across the NHS. However, there is ongoing uncertainty as to the optimal approach 3. Is there a need to recruit subjects who lack capacity? Eligible participants will be critically unwell and are likely to lack capacity as part of their underlying condition (e.g. acute hypoxia, sepsis). These individuals are an important COVID-19 group that are potentially at greater risk of deterioration. 4. In the context of the research is consent or consultation feasible? We have carefully considered the feasibility of seeking agreement from a personal or professional consultee in the context of this research. -Personal consultee-throughout the NHS, significant limitations have been placed on the visitation of COVID-19 patients. On this basis, a personal consultee will not be immediately physical available for consultation. Waiting for a personal consultee to attend the hospital would place the consultee at risk of infection and cause treatment delays. -Professional consultee-due to COVID-19, there will be extreme pressure on UK health services. In this context, we consider it impractical for hospital research teams to identify an appropriate medical practitioner to act as a professional consultee without delaying treatment. Does treatment need to be given quickly? 6) Might delay change the effect of treatment or the results? It is essential that treatment (as per the study arms) is initiated as soon as possible. Delays in treatment initiation may place the patient at risk, and increase the likelihood of the need for tracheal intubation and increase the risk of death. Delays may therefore make study interventions appear less effective by reducing any observed treatment effect. Patients will be assessed for capacity in the first instance and provided with the patient information sheet detailing the trial, the patient will be given adequate time to consider the trial before providing verbal consent. Version 4.0 29-May-2020 24 (47) 8. Would the legal representative/consultee be likely to have capacity? A consultee may have capacity, but consultation is impractical due to the urgent need to commence treatment and research context. 9 . Is it practical to consult a professional legal representative unconnected to the research? As per question four, the research context makes it impractical to consult a professional consultee. 10. What should the patient, consultee or legal representative be asked later? We will subsequently ask for patient consent or consultee agreement for ongoing delivery of the intervention (if applicable) and ongoing data collection. Patients will be assessed for capacity. Patients with capacity will be provided with verbal information about the trial and given a copy of the written participant information sheet. They will be given adequate time to review the information and ask questions. Due to ongoing concerns regarding risk of infection transmission, verbal consent only will be sought and documented on a study form and in the patient hospital records. Where a patient declines participation at this point they will not be entered into the study. For patients that lack capacity, it is not practical or appropriate to consult a guardian/welfare attorney prior to enrolment without placing the potential participant at risk of harm from delaying treatment. These processes will also not be feasible or safe to undertake in order to minimise risk of viral transmission to those involved. Significant limitations have been placed on the visitation of COVID-19 patients and therefore a guardian is unlikely to be immediately be available, and to attempt contact via telephone will delay treatment. Therefore these patients will not be entered into the study, see figure 3 . Following enrolment, the participant will be followed up regularly by the hospital research team. In participants that regain capacity, the site research team will approach the participant and provide verbal information about the trial. They will also be provided with the written participant information sheet, and given adequate time to review the information sheet and ask questions. Due to ongoing concerns regarding risk of infection transmission, verbal consent only will be sought and documented on a study form and in the patient hospital records. In participants that do not regain capacity by hospital discharge, an approach will be made to a personal consultee or professional consultee. The initial approach should ideally be made to a personal consultee. However, this will likely be precluded due to visiting restrictions, in which case the opinion of a professional consultee will be sought. The professional consultee will be a registered medical practitioner that is independent of the trial. The consultee will be provided with a verbal explanation of the trial and a copy of the written participant information sheet and cover note. If the consultee does not know of any objection to research participation expressed by the participant, they will be asked to verbally confirm this. This will be recorded on a study record form. capacity) at their place of residence to seek agreement. Up to three attempts to contact the participant will be made. Given the urgent need to answer this research question, for sites in England, Wales and Scotland, minimal personal identifiable data (NHS or CHI number, date of birth, postcode) will be submitted contemporaneously to Warwick Clinical Trials Unit. Patient identifiable information will not be transferred or retained by the WCTU for participants in Northern Ireland that do not provide consent. In the event that a trial participant declines consent to continue in the trial, personal identifiable data will be deleted. Information collected about the participant up to the point of withdrawal will be retained for analysis. In this trial, there may well be the possibility that the devices will not be available as a result of the challenging environment the clinical staff are presented with. For this reason, we will set up two randomisation systems, which will be integrated to maintain balance. Prior to randomisation, the clinician/nurse will check the availability of the devices. If no device is available then there will be no randomisation. If one of the devices is available (either CPAP or HFNO), then the clinician/nurse will choose the randomisation procedure which allocates standard care and CPAP or HFNO (system 1). If both devices are available, then system 2 will allow for an allocation using the three arms (standard care, CPAP or HFNO). These two systems will be integrated and constantly updated to ensure that the allocation ratio (1:1:1 for standard care: CPAP: HFNO) is maintained if possible. There is a possibility that this ratio will not be maintained and this has been compensated for in our sample size, which has been inflated accordingly. A simple and secure, interactive voice response (IVR) randomisation system has been established by the programming team at Warwick Clinical Trials Unit. A computer-generated randomisation sequence has been generated by the minimisation method. Patients will be stratified by site, gender (M/F), and age (<50, >=50 years). If a patient has been randomised and found to be ineligible or the device is not available, they will be included in the analysis on an intention-to-treat basis. Any data already collected will be retained and included in the analysis unless otherwise indicated. A back-up emergency randomisation system is currently being developed and full details will be made available and maintained on the trial website. Version 4.0 29-May-2020 28(47) Participants may be discontinued from the trial treatment and/or the trial at any time without prejudice. Unless a participant explicitly withdraws their consent, they should be followed-up wherever possible and data collected as per the protocol until the end of the trial. Patients in all three treatment groups will be intubated and receive invasive mechanical ventilation if clinically required. Continuous positive airway pressure will be administered according to local protocol/guidelines. Details of initial settings (CPAP Pressure and FiO2) will be recorded on the CRF. Administration of CPAP will not be protocolised and left to clinical discretion for management. High flow nasal oxygen will be administered according to local protocol/guidelines. Details of initial settings (Flow and FiO2) will be recorded on the CRF. Administration of HFNO will not be protocolised and left to clinical discretion for management. Standard care will comprise regular ward level oxygen therapy according to local protocol/guidelines, and excludes escalation to CPAP and HFNO. Administration of regular oxygen therapy will not be protocolised and left to clinical discretion for management. This is an open-label study. However, while the study is in progress, access to tabular results by treatment allocation will not be available to the research team, patients, or members of the Trial Steering Committee (unless the Data Safety Committee advises otherwise). In addition, the clinical staff delivering the interventions will not be blinded or masked, and therefore there is possibility that bias could be introduced by knowledge of treatment allocation through administration of interventions. Due to the exceptional circumstance of this study, it is not possible to protocolise the interventions or provide training for clinical staff to ensure that delivery of the treatment is standardised across the trial sites. We will assess this bias in the interim stages Committee and Trial Steering Committee. Both our primary and secondary outcomes are objective and this will ensure that detection bias is reduced. It is likely that the intervention the patient is randomised to may not be the one that is allocated or the patient may have crossed over to one of the other interventions. In this case, we will still include the patient in the trial on an intention-to-treat bias. However, we will do additional statistical analyses which will accommodate for patients who did not conform to the allocated intervention by means of a compliers analysis (as detailed in the statistical analysis section). The study will end when 4002 participants have been randomised and the last participant has completed final follow-up. The study will be stopped prematurely if:  Mandated by the Ethics Committee  Funding for the trial ceases The Ethics Committee that originally gave a favourable opinion of the study will be notified in writing if the study has been concluded or terminated early. A Serious Adverse Event (SAE) is an AE that fulfils one or more of the following criteria: These events will be included as part of the safety analysis for the trial and do not need to be reported separately to the Trial Coordinating Centre. The local PI will be responsible for confirming the relatedness of any AE to the trial intervention. If an AE occurs, the clinician responsible for the patient should decide whether it is safe to continue CPAP, with or without modification, or whether CPAP should be discontinued. AEs will be reviewed/monitored by the TMG for trends. For each SAE the following information will be collected from the investigator site:  full details in medical terms and case description  event duration (start and end dates, if applicable)  action taken  outcome  seriousness criteria  causality (i.e. relatedness to intervention), in the opinion of the investigator (Table 3) Once received, an independent causality assessment will be undertaken by the CI or clinical delegate. For any SAEs which are suspected to be caused by the trial intervention by either the CI or site clinician, expectedness will be confirmed by the CI or a delegate at WCTU. SAEs that are deemed to be unexpected and related to the study will be notified to the Research Ethics Committee (REC) within 15 days. All such events will be reported to the Sponsor, Trial Steering Committee and Data Monitoring Committee at their next meetings. All participants experiencing SAEs will be followed-up until the event has been resolved or a final outcome has been reached as per protocol until the end of the trial. Probable relationship There is evidence to suggest a causal relationship and the influence of other factors is unlikely. This event will be reported as related. There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out. This event will be reported as related. Because the trial is recruiting a population that is already in a life-threatening situation, it is expected that many of the participants will experience SAEs. Events that commonly occur in this population and those that are collected as outcomes of the trial should not be reported as SAEs. Principal Investigator (PI): Checking for AEs 5. Expedited reporting of related and unexpected SAEs to the REC within required timelines. 6. Notifying Investigators of related and unexpected SAEs that occur within the trial. Trial Steering Committee (TSC): In accordance with the Trial Terms of Reference for the TSC, periodically reviewing safety data and liaising with the DMC regarding safety issues. In accordance with the Trial Terms of Reference for the DMC, periodically reviewing unblinded overall safety data to determine patterns and trends of events, or to identify safety issues, which would not be apparent on an individual case basis. Death is collected as a study outcome. No separate notification of death is required. If any urgent safety measures are taken the CI/Sponsor shall immediately, and in any event no later than 3 days from the date the measures are taken, give written notice to the relevant REC of the measures taken and the circumstances giving rise to those measures. We will use the standard CTU study web-based application for study management and to record participant data (including case report forms) in accordance with the protocol. Clinical data will be collected during the ICU stay up to 30 days after randomisation or hospital discharge, whichever is later. Baseline characteristics collected include patient demographics, comorbidities, pre-admission function, inclusion/exclusion criteria, consent, time and date of randomisation, temperature at hospital admission, and COVID-19 diagnosis status. Data captured following randomisation will include initial device settings, duration of ventilation, prone therapy, ICU/hospital admission status, patient observations, AEs (treatment failure, need for other treatments, renal function, renal replacement therapy), survival status. Confirmation of COVID-19 diagnosis at any point will be recorded. Ethnicity, socioeconomic status and mortality will be reported from hospital records up until discharge and tracked after discharge using NHS Digital, the ICNARC and Research Centre and equivalent NHS data linkage in the devolved nations. ICU and hospital length of stay will be obtained from local centres or data linkage if appropriate. The case report form (CRF) has been developed by the CTU and made available to the participating sites as a paper and electronic CRF (eCRF) for ease of data collection; supporting materials will be available to staff. All documents will be stored safely in confidential conditions. On all trial-specific documents, other than the signed consent, the participant will be referred to by a unique trialspecific number/patient identifier/code in any database, not by name. The trial will be conducted in accordance with the current approved protocol, Good Clinical Practice (GCP), relevant data protection regulations and standard operating procedures (SOPs). A monitoring plan and risk assessment will be devised to protect participant safety and integrity of trial data. The database has been developed by the Programming Team at WCTU and all specifications (i.e. database variables, validation checks, screens) agreed between the programmer and appropriate trial staff. Version 4.0 29-May-2020 35(47) All essential documentation and trial records will be stored by WCTU in conformance with the applicable regulatory requirements and access to stored information will be restricted to authorised personnel. All data access will be controlled by generic usernames and passwords, and any changes to data will require the user to enter their username and password as an electronic signature in accordance with regulatory requirements. Staff will have access restricted to the functionality and data that are appropriate for their role in the study. Trial documentation and data will be archived for at least ten years after completion of the trial. Trial Master File and associated data will be archived by WCTU; trial data generated at study sites will be archived according to local policy. The maximum total sample size will be 4002 patients over the three intervention arms (1334 per arm). The primary end point will be a binary composite outcome of intubation or mortality within 30 days. An event (1) will be defined as intubation or death and an event (0) will be defined as no requirement for intubation and alive. In a systematic review and meta-analysis to evaluate the evidence for the use of HFNO against usual care in ARF 8 recent publication in the Lancet using WHO data on the cumulative number of deaths to March 1, 2020, mortality rates were reported to be 5·6% (95% CI 5·4-5·8) for China and 15·2% (12·5-17·9) outside of China 1 . Furthermore, in another study relating to the COVID-19, which assessed, lopinavir-ritonovir and standard care, in hospitalised adults with confirmed SARS-Cov-2 infection and with an oxygen saturation of <=94%, the mortality rate on standard care at day 28 was 25% 24 . In our sample size calculation, we have assessed both outcome measures and taken the largest in terms of the incidence, to ensure we have maximum power and sample size for our study. Therefore taking the data from Baud et al 1 to be representative of usual care and assuming a conservative incidence of 15% for the composite outcome of intubation or mortality on the usual care arm, then using a two-sided 5% significance level, a total 3000 patients (1000 per arm across 3 arms) would give approximately 90% power to detect an odds ratio of 0.625, corresponding to a reduction from 15% to 10% in the composite event rate. allowing for the 11 interim analyses. Our comparisons will be based on CPAP versus standard care and HFNO versus standard care and allow for the formal interim analyses as agreed with the DMC. However, there remain many uncertainties regards the sample size parameters and also whether an equal randomisation allocation ratio will be maintained. For this reason we have inflated our sample size to 4000 patients (4002 across the three arms) to maintain the study power and detect small effect sizes, if they exist. It may allow us to also assess the difference between CPAP and HFNO, if difference between these interventions are small enough to be detected with this larger sample size. Furthermore, it may be likely that we will not need all these patients if the trial stops at a formal interim analysis or if the DMC recommends that an arm is dropped. The formal stopping rules will be set out in the statistical analysis plan, following discussions with the DMC. These criteria will be used to accept or drop an intervention arm, based on the assessment of the primary outcome at each interim point. The statistical analysis will be based on intention to treat and will be conducted in line with the CONSORT statement 25 . For the overall analyses, numbers of events will be assessed using the logistic regression unadjusted and adjusted for important predictors, such as previous morbidities, age and gender) and results will be presented using odds ratios (with 95% confidence intervals). At the interim stages, the numbers of events will be analysed using the latter methods and compared to the p-value critical values. A final p-value and treatment effect estimate will be calculated adjusting for the interim analyses using the methods described by Jennison and Turnbull 26 , Fairbanks and Madsen 27 and, Emmerson and Fleming 28 . Intubation rates and mortality at 30 days will be assessed using the logistic regression models (both for adjusted and unadjusted analyses) and summarised using odds ratio (with 95% confidence intervals). Continuous secondary data will be presented using summary statistics and analysed using parametric or non-parametric methods depending on the distribution of the data. If possible, we will conduct a compliers average cause effect (CACE) analysis to assess the effect on the non-compliance to the allocation interventions (for all three interventions or two, if one is dropped) 29 . We anticipate no or very little missing data. However, in the case of missingness, we will use multiple imputation techniques (ICE procedures) to assess the missingness mechanisms. Recruitment will take place in 40 adult ICUs and centres to treat COVID-19 patients across the UK There will be no health economic evaluation within this trial. Version 4.0 29-May-2020 38(47) The University of Warwick will sponsor the study. Sub-contracts delegating responsibilities to research sites will be established using our standard contracting processes with NHS organisations. All required ethical approval(s) for the trial will be sought using the Integrated Research Application System. The trial will be conducted in accordance with all relevant regulations. Before enrolling patients into the trial, each trial site must ensure that the local conduct of the trial has agreement of the relevant NHS Trust Research & Development (R&D) department. Sites will not be permitted to enrol patients into the trial until all required agreements are in place. Annual reports will be submitted to the REC within 30 days of the anniversary date on which the favourable opinion was given, and annually until the trial is declared ended. The REC will be notified of the end of the trial (whether at planned time or prematurely). The CI will submit a final report to the required authorities with the results, including any publications within one year of the end of the trial. Peer review for this protocol will initially be provided by the Department of Health and Social Care and the NIHR Urgent Public Health prioritisation group. Additional peer review will be obtained as required. The trial is registered in advance of recruitment commencing, on the ISRCTN database comply with or variance from GCP and/or the final approved protocol. This results from error, fraud or misconduct. These cases should be documented in the protocol deviation and violation section of the case report form for the trial and appropriate corrective and preventative actions taken. Deviations will be included and considered when the clinical study report is produced, as they may have an impact on the analysis of the data. A "serious breach" is a breach which is likely to effect to a significant degree -(a) the safety or physical or mental integrity of the subjects of the trial; or (b) the scientific value of the trial The sponsor will be notified immediately of any case where the above definition applies during the trial conduct phase, and will notify the licensing authority in writing of any serious breach of (a) the conditions and principles of GCP in connection with that trial; or (b) the protocol relating to that trial, as amended from time to time, within 7 days of becoming aware of that breach NHS indemnity covers NHS staff, medical academic staff with honorary contracts, and those conducting the trial. NHS bodies carry this risk themselves or spread it through the Clinical Negligence Scheme for Trusts, which provides unlimited cover for this risk. The University of Warwick provides indemnity for any harm caused to participants by the design of the research protocol. These milestones are estimated and subject to change given the rapidly evolving circumstances under which this trial will be conducted. Trial coordination will be based at WMS/WCTU, University of Warwick. All day-to-day coordination of the study will be the responsibility of the Trial Manager. All clinical coordination of the study will be the responsibility of Professor Gavin Perkins. The study is managed by a multi-disciplinary team. The study office team will assist and facilitate the setting up of centres wishing to collaborate in the study. In addition the study office team will:  Distribute the standardised data collection forms to collaborators  Organise the telephone randomisation service for formal study entry  Monitor the collection of data, process data and seek missing data  Train local staff with regards to data collection remotely  Ensure the confidentiality and security of all study forms and data  Conduct extensive data checking and cleaning  Organise any interim and main analyses  Organise Steering Committee, DMC and Collaborators meetings The study office will receive completed data forms, via the online web application or email. Upon receipt, data forms will be checked for completeness and entered into a study specific dedicated computer programme which will check the data validity. The Trial Management Group, consisting of the project staff and co-investigators involved in the day-to-day running of the trial, will meet regularly throughout the project. Significant issues arising from management meetings will be referred to the Trial Steering Committee or Investigators, as appropriate. The trial will be guided by a group of respected and experienced personnel and trialists as well as at least one 'lay' representative. The TSC will have an independent Chairperson. Meetings will be held via teleconference or video conference at regular intervals determined by need but not less than once a year. Routine business is conducted by email, post or teleconferencing. The Steering Committee, in the development of this protocol and throughout the trial will take responsibility for: Membership of the TSC it to be confirmed. The full remit and responsibilities of the TSC will be documented in the Committee Charter which will be signed by all members. A DMC will be appointed comprising of two independent clinicians with experience in clinical trials and an independent statistician. They will be provided with interim reports with outcome measures, when data are available on 1000 patients, at 4 time points in the study. One of the independent clinicians will have experience in undertaking clinical trials in emergency or acute care. The DMC charter will be based on the DAMOCLES study group template. 35 Its roles will include: monitoring the data and making recommendations to the TSC on whether there are any ethical or safety reasons why the trial should not continue; making recommendations as to whether to drop any arm from the study for futility, either relative to standard care or to other arms; advising the TSC regarding the release of data and/or information; considering data emerging from other related studies. Membership of the DMC will be confirmed. DMC meetings will also be attended by the Chief Investigator and Trial Manager (for non-confidential parts of the meeting) and the trial statistician. The full remit and responsibilities of the DMC will be documented in the Committee Charter which will be signed by all members. A Trial Master File will be set up according to Warwick University SOP and held securely at the coordinating centre. The coordinating centre will provide Investigator Site Files to all recruiting centres involved in the trial. A full breakdown of costs, specifically 'Research' and 'NHS Service Support' costs, will be provided in due course. The study will be included on the NIHR Portfolio and is eligible for NHS Service Support costs. Version 4.0 29-May-2020 42(47) In this pragmatic trial, the precise delivery of study interventions will be at the discretion of the treating clinical team. We will record the delivery of interventions on the case report form, including unanticipated crossover between study arms. On-site monitoring will not be feasible in this trial, due to restrictions on non-essential staff visiting hospitals with COVID-19 patients. A risk-based proportionate approach outlined in the monitoring plan for off-site monitoring will be developed through discussion with the trial sponsor, that takes account of the challenging circumstances in which this trial will operate and the extreme pressure that will be placed on hospital staff. Protocol deviations or violations (and actions taken to prevent recurrence) will be recorded in the case report form. Serious breaches of the study protocol or GCP should be immediately reported to the Chief Investigator. The Chief Investigator in consultation with the PI will take whatever immediate action is required to safeguard the wellbeing of participant. The Chief Investigator will notify the Sponsor immediately and Ethics committee within 7 days of becoming aware of the serious breach. Co-enrolment with other trials will be reviewed on a case-by-case basis in accordance with national NIHR-supported co-enrolment guidelines 30 . There are many current examples of successful coenrolment between UK critical care studies, facilitated by these guidelines. Three members of Royal College of Anaesthetist Patient Carer Public Involvement Engagement (PCPIE) were approached to give their opinion on research question, study design, appropriateness of emergency consent and patient facing documents. PCPIE members were unanimous in their support for the research question and considered the study to be highly relevant to patients and public. They opined that it is critical and urgent to find the optimal breathing support for patients to avoid invasive ventilation and improve patient survival. They were also particularly supportive of the adaptive pragmatic study design and planned rapid dissemination of study results. Emergency Version 4.0 29-May-2020 43(47) consent was considered both appropriate in a very difficult and time critical situation and sensitive in limiting burden to patient and family. Furthermore, we also consulted with an independent member of the Clinical Research Ambassador Group, University Hospitals Birmingham NHS Foundation Trust with extensive experience of contributing to emergency care trials. This PPI colleague was supportive and confirmed our approach of emergency consent given the challenging clinical circumstances and urgency with which treatment of potential benefit should be delivered to patients, advising that they felt it would be considered acceptable to patients and members of the public. Planned use of data without consent was also agreed as being necessary, and acceptable. In addition, investigating optimum ventilation practice was prioritised in a 2014 James Lind Alliance Priority Setting Partnership for intensive care research involving patients and family representatives 31 , and subsequently in a NIHR critical care research priority setting survey 32 . We will continue to engage patients and family members at later stages of the trial conduct where possible, such as dissemination of findings. The University of Warwick (Research Impact Services, University of Warwick, Coventry CV4 7AL) is the Sponsor for the study. The study is being conducted in full adherence with the principles of the Declaration of Helsinki and MRC Good Clinical Practice principles and guidelines. It also complies with all applicable UK legislation and Warwick Standard Operating Procedures. All data are being stored securely and held in accordance with the Data Protection Act 2018. All identifiable data are pseudonymised and treated as confidential. All CRFs, questionnaires, study reports and communication regarding the study will identify the patients by the assigned unique trial identifier and initials only. Patient confidentiality will be maintained at every stage and identifiable information will not be made publicly available to the extent permitted by the applicable laws and regulations. The trial consent process ensures that patients have the choice of whether or not to continue to participate in data collection and are given all relevant information about the study to make an informed decision. Participants are informed that they are free to withdraw from the trial at any time during any phase without providing a reason and without prejudice, if they so wish. The approach will be informed by WCTU The results of the trial will be reported first to trial collaborators. The main report will be drafted by the trial coordinating team, and the final version will be agreed by the Trial Steering Committee before submission for publication, on behalf of the collaboration. The success of the trial depends on the collaboration of doctors, nurses and researchers from across the UK. Equal credit will be given to those who have wholeheartedly collaborated in the trial. The trial will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines (www.consort-statement.org). The results of the trial will be shared widely, and participants are able to request a copy of the results through contacting the local study team. Following the conclusion of the trial, summary information will be sent to surviving participants who recorded a desire to receive this information. Given the circumstances under which this trial will be conducted, we have specifically built in resilience to support all relevant personnel involved. There are two Chief Investigators, two statisticians, five further respiratory/critical care physicians, two respiratory physiotherapists, and key WCTU representation, with additional access to the full team of trial managers, coordinators and other staff within the CTU. In addition, we adopt the same approach when identifying members of the TSC and DMC. Real estimates of mortality following COVID-19 infection. The Lancet Infectious Diseases 2020 and Wales Mortality during the COVID-19 outbreak ICNARC report on COVID-19 in critical care Clinical Characteristics of Coronavirus Disease 2019 in China Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) High-flow nasal cannulae for respiratory support in adult intensive care patients The Effect of High-Flow Nasal Cannula Oxygen Therapy on Mortality and Intubation Rate in Acute Respiratory Failure: A Systematic Review and Meta-Analysis. Read Online: Critical Care Medicine | Society of The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and metaanalysis High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure The Australian and New Zealand Intensive Care Society (ANZICS) COVID-19 Guidelines Noninvasive positive pressure ventilation for acute respiratory failure following upper abdominal surgery Continuous positive airway pressure and noninvasive ventilation in prehospital treatment of patients with acute respiratory failure: a systematic review of controlled studies Prehospital Continuous Positive Airway Pressure for Acute Respiratory Failure: A Systematic Review and Meta-Analysis Guidance for the role and use of non-invasive respiratory support in adult patients with coronavirus (confirmed or suspected) Noninvasive Ventilation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Guide to the design and review of emergency research when it is proposed that consent and consultation be waived National Respiratory Audit Programme annual report Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials Group Sequential Methods with Applications to Clinical Trials P values for tests using a repeated significance test design Parameter estimation following group sequential hypothesis testing Estimating causal effects in trials involving multitreatment arms subject to non-compliance: a Bayesian framework Co-Enrolment to Intensive Care Studies -A UK Perspective